8-K

U.S. SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549

FORM 8-KCURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934Date of Report (Date of earliest event reported) December 5, 2012GREATBATCH, INC.
(Exact name of registrant as specified in its charter)

Delaware	1-16137	16-1531026
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2591 Dallas Parkway, Frisco, Texas	75034
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code (716) 759-5600

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 5, 2012, Greatbatch, Inc. (the “Company”) issued a press release announcing the election of Rudy A. Mazzocchi to its Board of Directors (the “Board”).  Mr. Mazzocchi also will serve on the Board’s Technology Development & Innovation and Corporate Governance & Nominating Committees.   As a Director, he will be entitled to receive remuneration in accordance with the Company’s Director compensation program disclosed in the Company’s most recent proxy statement dated April 20, 2012. Mr. Mazzocchis’ term as Director will last until the next annual meeting of stockholders.

Mr. Mazzocchi brings over 25 years of experience in the medical device industry.  He is currently Chief Executive Officer of ELENZA, Inc., a company developing the world’s first electronic “AutoFocal” intraocular lens, a position he has held since 2010.  From 2008 to 2010, Mr. Mazzocchi was President & Chief Executive Officer of NoraVision, Inc., a neuro-opthalmoc device company specializing in non-invasive photic neurostimulation.  From 2006 to 2008, he served as Managing Director  of Accuitive Medical Ventures, a venture capital fund established to finance and develop early and expansion stage medical device and technology companies.  Mr. Mazzocchi also served as President & Chief Executive Officer of Image-Guided Neurologics from 1998 to 2005.  Prior to that, he served in a number of management and operations roles at Microvena Corporation and Cook Critical Care.

A copy of the press release is filed as exhibit 99.1 to this report.

Item 9.01.  Financial Statements and Exhibits

(d) Exhibits

99.1 Press Release dated December 5, 2012.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated:	December 5, 2012	GREATBATCH, INC.
		By:	/s/ Michael Dinkins
			Michael Dinkins
			Senior Vice President and
			Chief Financial Officer

EX-99.1

Exhibit 99.1

Greatbatch, Inc. Elects Rudy A. Mazzocchi to its Board of Directors

CLARENCE, N.Y.--(BUSINESS WIRE)--December 5, 2012--Greatbatch, Inc. (the “Greatbatch”) (NYSE: GB) announced that Rudy A. Mazzocchi has been elected to its Board of Directors. Mr. Mazzocchi also will serve on the Board’s Technology Development & Innovation and Corporate Governance & Nominating Committees.

“We welcome Rudy Mazzocchi to our Board of Directors,” said Bill R. Sanford, Greatbatch’s Chairman. “He has an impressive medical industry background, and his extensive executive experience in an expanding business environment will be especially beneficial to Greatbatch.”

“I look forward to working together with Rudy and the other Greatbatch Board members to deliver increased value for our stockholders,” commented Thomas J. Hook, President & Chief Executive Officer of Greatbatch. “His knowledge and insights will make a significant contribution to our company.”

Mr. Mazzocchi brings over 25 years of experience in the medical device industry. He is currently Chief Executive Officer of ELENZA, Inc., a company developing the world’s first electronic “AutoFocal” Intraocular Lens, a position he has held since 2010. From 2008 to 2010, Mr. Mazzocchi was President & Chief Executive Officer of NovaVision, Inc., a neuro-ophthalmology device company specializing in non-invasive photic neurostimulation to restore vision. From 2006 to 2008, he served as Managing Director of Accuitive Medical Ventures, a venture capital fund established to finance and develop early and expansion stage medical device and technology companies. Mr. Mazzocchi also served as President & Chief Executive Officer of Image-Guided NEUROLOGICS from 1998 to 2005. Prior to that, he was the founding-CEO of MICROVENA Corporation, now currently known as eV3, and served in numerous management and operations roles at Cook Critical Care, an operating division of COOK, Inc..

About Greatbatch, Inc.

Greatbatch, Inc. (NYSE: GB) provides top-quality technologies to industries that depend on reliable, long-lasting performance through its brands Greatbatch Medical, Electrochem and QiG Group. Greatbatch Medical develops and manufactures critical medical device technologies for the cardiac, neurology, vascular and orthopaedic markets. Electrochem designs and manufactures battery and wireless sensing technologies for high-end niche applications in the energy, military, portable medical, and other markets. The QiG Group empowers the design and development of new medical devices for our core markets.

CONTACT:
Greatbatch, Inc.
Marco F. Benedetti, 716-759-5856
Vice President Financial Planning and Analysis,
Investor Relations & Treasurer
mbenedetti@greatbatch.com